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Mutations in isocitrate dehydrogenase (IDH)-1 or -2 are found in the majority ofWHO grade
II and III astrocytomas and oligodendrogliomas, and secondary glioblastomas. Almost all
described mutations are heterozygous missense mutations affecting a conserved arginine
residue in the substrate binding site of IDH1 (R132) or IDH2 (R172). But the exact mech-
anism of IDH mutations in neoplasia is not understood. It has been proposed that IDH
mutations impart a “toxic gain-of-function” to the mutant protein, however a dominant-
negative effect of mutant IDH has also been described, implying that IDH may function
as a tumor suppressor gene. As most, if not all, tumor suppressor genes are inactivated
by epigenetic silencing, in a wide variety of tumors, we asked if IDH1 or IDH2 carry the
epigenetic signature of a tumor suppressor by assessing cytosine methylation at their pro-
moters. Methylation was quantified in 68 human brain tumors, including both IDH-mutant
and IDH wildtype, by bisulfite pyrosequencing. In all tumors examined, CpG methylation
levels were less than 8%. Our data demonstrate that inactivation of IDH function through
promoter hypermethylation is not common in human gliomas and other brain tumors.These
findings do not support a tumor suppressor role for IDH genes in human gliomas.
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INTRODUCTION
Mutations in isocitrate dehydrogenase (IDH)-1 or-2 are found in
the majority of WHO grade II and III astrocytomas and oligo-
dendrogliomas, and secondary glioblastomas (Parsons et al., 2008;
Yan et al., 2009). IDH mutations are also found in some myeloid
malignancies and chondroid tumors (Amary et al., 2011). IDH
mutations occur early in gliomagenesis (Watanabe et al., 2009),
suggesting that low grade diffuse gliomas share a common pathway
in their development. Patients with high-grade gliomas carry-
ing IDH mutations have significantly better survival than those
with wildtype IDH tumors and also respond better to treat-
ment (Parsons et al., 2008; Yan et al., 2009; Houillier et al.,
2010). In addition, IDH mutation status is useful in assisting
diagnostic classification: the majority of astrocytomas, oligoden-
drogliomas, and secondary glioblastomas harbor IDH mutations
while almost all primary glioblastomas do not (reviewed in Gupta
et al., 2011).
Isocitrate dehydrogenase is one of several citric acid cycle
enzymes implicated in neoplasia. Mutations in all four subunits of
succinate dehydrogenase (SDH) underlie a variety of sporadic and
inherited paragangliomas and pheochromocytomas (Sudarshan
et al., 2007), while mutations in fumarate hydratase are associated
with hereditary leiomyomatosis and renal cell cancer and some
cases of isolated type 2 papillary renal cell carcinoma (Gardie et al.,
2011). SDH and fumarate hydratase are thought to act as tumor
suppressor genes, with cancers exhibiting the “two-hits” typical of
tumor suppressor gene inactivation (reviewed in Wallace, 2012).
Almost all described IDH mutations in gliomas are heterozy-
gous missense mutations focused on a few conserved residues
in the enzymes’ substrate binding sites. IDH mutations have
thus been proposed to impart a toxic gain-of-function to the
resultant protein (Dang et al., 2009). A salient biochemical fea-
ture of cells carrying mutant IDH is increased R-2 hydroxyglu-
tarate (2HG) production via consumption of αKG and NADPH
(Dang et al., 2009). But mature IDH1 and IDH2 enzymes are
homodimeric, and it has also been demonstrated that mutant
IDH1 exerts a dominant-negative effect on IDH function through
mutant/wildtype heterodimer formation (Zhao et al., 2009); this
scenario would lead to a direct effect on αKG and NADPH levels.
We and others have previously reported loss of heterozygosity at
the IDH1 locus in gliomas and leukemias (Ichimura et al., 2009;
Zhang et al., 2011; Gupta et al., 2012), and monoallelic expression
of IDH1 in gliomas is not uncommon (Walker et al., 2012). Fur-
thermore a recent report characterizes several rare but recurrent
IDH mutations that result in loss-of-function without elevation
of 2HG (Ward et al., 2012). Taken together, these findings sug-
gest that at least in some circumstances IDH1 and/or IDH2 may
function as a typical tumor suppressor gene.
As promoter hypermethylation is one hallmark of tumor sup-
pressor genes in a variety of tumors (Baylin and Herman, 2000),
we asked if IDH genes may carry this particular epigenetic sig-
nature of a tumor suppressor by assessing cytosine methylation
at their respective promoters. Our study is the first to specifically
examine IDH promoter methylation in tumors.
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MATERIALS AND METHODS
TUMORS SAMPLES
Tumors were obtained from the Royal Prince Alfred Hos-
pital tumor and tissue bank following appropriate institu-
tional human research ethics approval. Histological diagnoses
were provided by an experienced neuropathologist (Michael
E. Buckland). The tumor samples included gliomas with a
variety of IDH1 mutations, as well as IDH-wildtype tumors
(Table 1) and three samples of non-neoplastic brain. Also
included in the group were two tumors with a proven IDH1
mutation, but with absent staining by the IDH1 mutation-
specific antibodies H09 and SMab-1 (see below). All other
tumors with IDH1 R132H or R132S mutations showed posi-
tive immunostaining with H09 or SMab-1 antibodies, respec-
tively.
IMMUNOHISTOCHEMISTRY
Monoclonal antibodies against IDH1 R132H (clone H09;
Dianova, Germany) and IDH1 R132S (kind gift from Dr.
Y. Kato, Japan) were used at 1:500 dilution on 5µm-FFPE
tumor sections. Following antigen retrieval in 10 mM sodium
citrate buffer pH 6.0, for 20 min at 125˚C, sections were
incubated in primary antibodies for 1 h at room tempera-
ture, and antibody detection was performed using the Dako
Envision system, according to the manufacturer’s instruc-
tions.
DNA EXTRACTION AND BISULFITE MODIFICATION
DNA was extracted from 100 mg of frozen tumor tis-
sue using the Qiagen DNeasy blood and tissue kit (Qia-
gen, Hilden, Germany), and bisulfite modification was per-
formed using the Qiagen Epitect Bisulfite Kit (Qiagen,
Hilden, Germany), according to the manufacturer’s instruc-
tions.
PROMOTER METHYLATION ANALYSIS
Methylation status of the IDH1 and IDH2 promoter regions were
assessed using Qiagen’s Pyromark CpG assays, Hs_IDH1_01_PM
and Hs_IDH2_01_PM, respectively (see Figure 1). Pyrograms
were analyzed using Pyromark Q24 software (Qiagen, Hilden, Ger-
many), version 2.0.6, to calculate percentage methylation at each
CpG and mean methylation across all CpGs for each sample was
calculated.









Glioblastoma 30 8 1.7±0.9 1.7±0.5
Astrocytoma 7 6 2.6±0.8 3.0±1.3
Oligodendroglioma 10 9 2.2±0.7 2.1±0.8
Pilocytic astrocytoma 2 0 2.1±0.4 1.9±0.0
Meningioma 16 0 2.3±1.2 3.4±1.6
Adenocarcinoma 3 0 2.2±0.4 2.6±0.9
Non-neoplastic brain 3 n/a 3.0±1.75 3.9±0.9
IDH1 AND IDH2 MUTATION ASSESSMENT
In tumors that were negative for IDH R132H immunostaining,
IDH1 and IDH2 mutation status was determined by direct DNA
sequencing. The fourth exons of IDH1 and IDH2 were PCR
amplified in separate reactions using primer pairs CATTTGTCT-
GAAAAACTTTGCTT and TCACATTATTGCCAACATGAC for
IDH1, and GGTTCAAATTCTGGTTGAAAGATG and GCTAG-
GCGAGGAGCTCCAGT for IDH2. Each reaction consisted of
50 mM Tris/HCl, 10 mM KCl, 5 mM (NH4)2SO4, 2 mM MgCl2,
0.2 mM each dNTP, 2 U FastStart Taq polymerase (Roche, Man-
heim, Germany), 0.5µM each primer, and 2µL of extracted DNA
in a total volume of 20µL. Cycling conditions were, initial denatu-
ration at 95˚C for 5 min, followed by 40 cycles of 95˚C for 30 s, 60˚C
for 30 s, and 72˚C for 30 s. PCR products were sequenced direction-
ally using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems), and sequencing reaction products were resolved on
a 3730xl DNA Analyzer (Applied Biosystems), according to the
manufacturer’s instructions.
STATISTICS
Two-tailed Student t -test was used to compare mean IDH1 and
IDH2 promoter methylation levels between IDH-mutant and
wildtype tumors.
RESULTS
Figure 1 shows the promoter regions of IDH1 and IDH2, the CpG
island within these regions, and the sequences targeted for bisul-
fite pyrosequencing. The IDH1 assay targets four contiguous CpG
sites, 275 bp upstream of the transcription start site. The IDH2
assay targets eight CpG sites 425 bp upstream from the transcrip-
tion start site. The CpGs targeted by these assays lie within CpG
islands that are adjacent to, or span, the transcription start site of
the gene. Typical pyrograms obtained for patient samples for both
IDH1 and IDH2 assays are shown in Figure 2.
A total of 68 brain tumors were assessed for IDH1 and
IDH2 promoter methylation status. Tumors examined consisted
of 49 gliomas, 16 meningiomas, and 3 metastatic adenocarcino-
mas. Twenty five IDH1 mutations were present in the gliomas
tested (23×R132H, 1×R132S, and 1×R132L); no IDH2-mutant
tumors were present. Two of the mutant tumors (1×R132H and
1×R132S) were consistently negative for mutant protein expres-
sion on immunohistochemistry; all other R132H-mutant tumors
were immunopositive with H09 antibody. Table 1 shows the num-
ber of tumor types examined, their IDH1 mutation status, and
mean promoter methylation levels for IDH1 and IDH2. Table A1 in
Appendix details the tumor type, WHO grade, IDH mutation sta-
tus, and the methylation levels at each individual CpG dinucleotide
for all samples included in this study.
For IDH1, mean of methylation across all tumors was 2%
(below the reported detection limit of pyrosequencing; Mikeska
et al., 2011), with average methylation across the four CpGs
assayed for each sample ranging from 0.3 to 5.3%. The high-
est methylation level detected (5.3%) was in a secondary
glioblastoma that harbored an IDH1 R132H mutation. No
other samples in the study showed methylation above 5% at
the IDH1 promoter (Table A1 in Appendix). The three non-
neoplastic brain samples had an average methylation level of
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FIGURE 1 | Bisulphite Pyrosequencing designs. Schematics showing regions targeted for methylation analysis and their relationships with CpG islands and
transcription start sites of IDH1 and IDH2.
3%. There was no significant difference in mean methylation
levels between wildtype tumors and those harboring an IDH1
mutation.
For IDH2, average methylation across all tumor samples was
2.3%, and the highest average methylation across the eight CpGs
assayed shown by any sample was 7.1% in a meningioma (Table A1
in Appendix). Three non-neoplastic control brain samples had
an average methylation level of 3.9%. Only one other sample,
also a meningioma, recorded an average methylation at the IDH2
promoter above 5%. In vitro methylated genomic DNA (Qia-
gen, Hilden, Germany) showed average methylation of 85.2 and
87.7% for the IDH1 and IDH2 loci, respectively, confirming assay
performance.
Two gliomas in our cohort were found to harbor IDH1 muta-
tions when subjected to DNA sequencing, but exhibited no pro-
tein expression by immunohistochemistry, despite repeated test-
ing. Following negative immunohistochemistry results, we were
able to extract DNA from the slide used for immunostaining,
and confirm the presence of IDH1 mutation, excluding tissue
mosaicism as a cause of these results. The two IDH-mutant
tumors without detectable mutant protein expression showed
mean IDH1 methylation levels of 2.8% (R132H), and 1.8%
(R132S) only.
DISCUSSION
In this study, we quantified methylation levels within the CpG
island associated with the promoter regions of both IDH1 and
IDH2 by bisulfite pyrosequencing. We hypothesized that if IDH1
and IDH2 functioned as tumor suppressor genes, then some
tumors may exhibit dense hypermethylation of the CpG island
associated with their promoter region. Loss of gene expression
associated with promoter methylation is a well described phenom-
enon in a variety of tumors (Baylin and Herman, 2000). However,
none of the 68 tumors examined exhibited this epigenetic hallmark
of tumor suppressor genes.
Three IDH enzymes are present in mammalian cells, IDH1,
IDH2, and IDH3. IDH3 utilizes NAD+ as the reducing agent
in an irreversible reaction to convert mitochondrial isocitrate
to αKG, while both IDH1 and IDH2 utilize NADP+ to convert
isocitrate to αKG in a reversible fashion. To date, IDH3 muta-
tions have not been implicated in neoplasia. Mutant IDH1 and
IDH2 enzymes exert a novel biochemical effect, namely the pro-
duction of 2HG, via consumption of αKG and NADPH (Dang
et al., 2009). 2HG is a competitive inhibitor of αKG-dependant
enzymes such as histone lysine methyltransferases and the TET
family of 5-methylcytosine hydroxylases. Both reduced αKG and
increased 2HG levels converge to alter the cellular epigenetic
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FIGURE 2 | Representative pyrograms.Typical pyrograms obtained from patient samples for IDH1 (A) and IDH2 (B). Each pink shaded column indicates a
CpG dinucleotide assayed, and the percentage of methylation at that CpG dinucleotide is indicated above. The blue shaded boxes are internal bisulfite
modification control assessments.
landscape; in vitro transfection of mutant IDH into immortal-
ized astrocytes results in increased histone methylation and a
gradual rise in DNA methylation levels (Lu et al., 2012). In
addition, the recently described glioma CpG island hypermethy-
lator phenotype is associated with IDH mutations (Turcan et al.,
2012).
IDH1 is also the major source of non-mitochondrial NADPH
in humans, which is important in the control of oxidative dam-
age. Either loss-of-function or gain-of-function of IDH will
result in reduced cytoplasmic NADPH levels and susceptibil-
ity to oxidative stress (Reitman and Yan, 2010). It may be
that neomorphic production of 2HG and decreased enzymatic
activity are both involved in tumor development, but in differ-
ent contexts. In support of this, rare IDH mutations in lym-
phoma, pediatric glioblastoma, and thyroid cancer have demon-
strated loss-of-function effects (Ward et al., 2012). Assessment
of IDH promoter methylation in these tumor types may assist
in determining if tissue-specific roles exist for IDH mutations in
cancer.
Monoallelic expression of IDH1 has recently been reported in
12 out of 67 gliomas with IDH1 mutations (Walker et al., 2012),
with expression occurring only from the wildtype allele in 10 of
12 cases. Preferential or exclusive expression of the wildtype IDH1
allele was associated with significantly poorer outcomes (Walker
et al., 2012). Included in our cohort were two tumors harboring
IDH1mutations but without detectable mutant protein expression
by immunohistochemistry, raising the possibility of monoallelic
expression from the wildtype allele. However, neither of these
tumors showed significant promoter methylation, excluding this
epigenetic regulatory mechanism as the cause of undetectable
mutant protein. Further studies into the mechanism(s) involved
in monoallelic expression and its role in progression of glioma and
other cancers will provide additional insights into the role of IDH
in neoplasia.
Molecular testing for IDH mutations is useful in the clini-
cal setting in assisting diagnostic classification and as a prog-
nostic indicator. While there is a routinely used, specific anti-
body for IDH1 R132H mutations, it is becoming common
to screen tumors with negative IDH immunostaining using
DNA based techniques. The identification of monoallelic expres-
sion of IDH1 in glioma raises potential issues in the clini-
cal interpretation of these molecular analyses. It may be that
monoallelic (or even skewed) gene expression could compro-
mise the prognostic utility of DNA testing for a subset of
tumors.
In this study, we have demonstrated that promoter hyper-
methylation of IDH1 and IDH2 genes is absent or very rare in
human gliomas and other brain tumors. These findings do not
support a tumor suppressor gene mechanism for IDH in human
gliomas. However the occurrence of uncommon inactivating IDH
mutations, loss of heterozygosity of IDH in some tumors, and
monoallelic expression of IDH1 in some gliomas points to as
yet uncharacterized mechanisms of disease associated with IDH
dysfunction.
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APPENDIX
Table A1 | Detailed results of tumours tested.
Tumor type Grade Mutation
status
IDH1 methylation (%) IDH2 methylation (%)
CPG1 CPG2 CPG3 CPG4 AVG CPG1 CPG2 CPG3 CPG4 CPG5 CPG6 CPG7 CPG8 AVG
Astrocytoma III R132H 3 1 1 1 1.5 2 2 1 1 2 4 1 4 2.1
Astrocytoma II R132H 4 1 1 1 1.8 1 2 1 1 1 4 1 4 1.9
Astrocytoma III R132H 6 3 3 3 3.8 4 5 3 3 2 8 2 6 4.1
Astrocytoma III R132H 6 3 3 3 3 3 5 3 2 2 9 2 7 4.1
Glioblastoma IV R132H 4 3 5 9 5.3 2 3 1 1 1 4 1 2 1.9
Glioblastoma IV R132H 2 1 1 1 1.3 1 1 1 1 1 2 1 2 1.3
Glioblastoma IV R132H 2 1 1 1 1 1 0 0 0 1 3 1 5 1.4
Glioblastoma IV R132H 1 1 1 1 1 1 1 0 0 1 3 1 3 1.3
Glioblastoma IV R132H 2 1 1 1 1.3 1 1 1 0 2 3 1 6 1.9
Glioblastoma IV R132H 2 1 1 1 1.3 1 1 1 0 1 3 1 5 1.6
Glioblastoma IV R132H 2 1 1 1 1.3 0 1 0 0 0 2 0 2 0.6
Oligodendroglioma III R132H 4 1 1 1 1.8 1 2 1 1 1 3 1 3 1.6
Oligodendroglioma III R132H 4 1 2 1 2 1 2 1 1 1 4 1 4 1.9
Oligodendroglioma III R132H 4 2 2 1 2.3 3 2 1 1 1 4 1 3 2
Oligodendroglioma III R132H 4 2 2 1 2.3 1 3 1 1 1 4 1 3 1.9
Oligodendroglioma III R132H 4 2 1 1 2 1 2 1 1 1 4 1 3 1.8
Oligodendroglioma III R132H 4 2 2 1 2.3 2 3 1 1 1 5 1 3 2.1
Oligodendroglioma II R132H 4 1 1 1 1.8 1 2 1 1 1 5 1 4 2
Oligodendroglioma II R132H 3 1 1 1 1.5 1 2 1 1 1 5 1 2 1.8
Oligodendroglioma II R132H 4 2 1 1 2 1 2 1 1 1 4 1 3 1.8
Oligodendroglioma III R132H 7 3 3 3 4 4 6 3 3 3 9 2 6 4.5
Astrocytoma* III R132H* 5 2 2 2 2.8 2 4 2 3 4 7 2 4 3.5
Astrocytoma III R132L 4 2 2 1 2.3 2 3 2 2 6 7 2 11 4.4
Glioblastoma* IV R132S* 2 1 4 0 1.8 2 2 1 1 1 3 1 3 1.8
Adenocarcinoma N/A Wildtype 4 2 2 1 2.3 1 2 1 1 2 5 1 4 2.1
Adenocarcinoma N/A Wildtype 3 2 1 1 1.8 2 2 1 1 1 5 1 4 2.1
Adenocarcinoma N/A Wildtype 4 2 2 2 2.5 3 3 2 2 2 7 2 8 3.6
Astrocytoma III Wildtype 6 2 2 2 3 0 0 0 0 0 6 0 3 1.1
Glioblastoma IV Wildtype 4 2 2 1 2.3 2 2 2 2 1 4 1 3 2.1
Glioblastoma IV Wildtype 4 2 3 3 3 2 2 1 1 2 5 1 3 2.1
Glioblastoma IV Wildtype 4 1 0 0 1.3 2 2 0 1 1 4 0 3 1.6
Glioblastoma IV Wildtype 4 2 2 2 2.5 2 2 1 1 2 4 1 5 2.3
Glioblastoma IV Wildtype 3 2 2 2 2.3 2 3 2 1 1 4 1 4 2.3
Glioblastoma IV Wildtype 1 1 1 2 1.3 2 2 1 1 1 2 1 3 1.6
Glioblastoma IV Wildtype 2 1 1 1 1.3 1 2 2 1 2 3 1 8 2.5
Glioblastoma IV Wildtype 1 0 0 0 0.3 1 1 1 1 1 2 1 3 1.4
Glioblastoma IV Wildtype 3 2 2 2 2.3 2 2 1 1 0 5 0 0 1.4
Glioblastoma IV Wildtype 3 1 1 1 1.5 2 2 1 2 1 4 1 3 2
Glioblastoma IV Wildtype 3 2 3 3 2.8 2 2 1 1 1 4 1 4 2
Glioblastoma IV Wildtype 3 1 1 1 1.5 3 3 2 2 2 4 1 4 2.6
Glioblastoma IV Wildtype 2 1 1 1 1.3 1 2 1 1 1 4 1 4 1.9
Glioblastoma IV Wildtype 3 1 2 2 2 2 2 1 1 1 3 1 3 1.8
Glioblastoma IV Wildtype 2 1 1 1 1.3 1 2 1 1 1 3 1 3 1.6
Glioblastoma IV Wildtype 1 0 1 1 0.8 0 0 0 0 1 0 0 4 0.6
Glioblastoma IV Wildtype 3 1 1 1 1.5 0 1 0 0 1 3 0 2 0.9
(Continued)
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Table A1 | Continued
Tumor type Grade Mutation
status
IDH1 methylation (%) IDH2 methylation (%)
CPG1 CPG2 CPG3 CPG4 AVG CPG1 CPG2 CPG3 CPG4 CPG5 CPG6 CPG7 CPG8 AVG
Glioblastoma IV Wildtype 1 0 1 1 0.8 1 1 0 1 2 3 1 3 1.5
Glioblastoma IV Wildtype 2 1 1 1 1.3 0 0 0 0 1 3 0 5 1.1
Glioblastoma IV Wildtype 2 1 1 1 1.3 1 2 1 1 1 4 1 4 1.9
Glioblastoma IV Wildtype 2 1 1 1 1.3 1 1 1 1 2 3 1 3 1.6
Glioblastoma IV Wildtype 2 1 1 1 1.3 0 1 0 0 1 3 1 2 1
Meningioma I Wildtype 4 1 2 1 2 3 2 3 2 5 8 4 30 7.1
Meningioma I Wildtype 3 2 1 1 1.8 2 2 2 1 4 7 2 12 4
Meningioma I Wildtype 4 2 1 1 2 2 3 1 1 2 4 1 5 2.4
Meningioma I Wildtype 3 1 1 1 1.5 1 2 1 1 1 5 1 4 2
Meningioma I Wildtype 4 2 2 1 2.3 1 3 1 1 2 5 1 5 2.4
Meningioma I Wildtype 2 1 0 0 0.8 1 1 1 1 1 4 1 8 2.3
Meningioma I Wildtype 2 1 1 1 1.3 1 2 1 1 1 3 1 4 1.8
Meningioma I Wildtype 2 1 1 0 1 2 2 2 2 4 7 3 12 4.3
Meningioma II Wildtype 3 1 1 1 1.5 1 3 0 1 1 4 1 5 2
Meningioma I Wildtype 2 1 1 1 1.3 1 2 2 1 1 4 1 5 2.1
Meningioma I Wildtype 2 1 1 1 1.3 0 1 1 0 1 3 0 4 1.3
Meningioma I Wildtype 6 3 3 3 3.8 3 6 3 3 3 9 2 8 4.6
Meningioma II Wildtype 7 3 4 2 4 4 6 3 3 2 10 3 8 4.9
Meningioma I Wildtype 7 3 3 3 4 3 6 3 2 3 9 2 9 4.6
Meningioma II Wildtype 7 3 3 3 4 4 5 3 3 3 10 3 11 5.3
Meningioma I Wildtype 5 3 3 3 3.5 2 4 2 2 2 8 1 7 3.5
Pilocytic astrocytoma I Wildtype 4 2 2 1 2.3 2 2 1 1 1 4 1 3 1.9
Pilocytic astrocytoma I Wildtype 3 1 2 1 1.8 1 1 2 1 1 4 1 4 1.9
t -Test WTvs MUT (all tumors) 0.155 0.230 0.162 0.242 0.194 0.448 0.319 0.387 0.391 0.431 0.414 0.436 0.090 0.298
Methylation is reported as a percentage of methylated alleles. Mutated tumours with absent mutant protein are marked by *.
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